The disclosure relates to hematological parameters of viral infection. More specifically, the present disclosure relates to automated volume biomarkers lymph index and monocyte distribution width (MDW) for early detection of Coronavirus infection. The invention also relates to a method, device and computer executable program for early diagnosis of SARS-CoV-2 infection using volume biomarker lymph index and monocyte distribution width (MDW). According to some technical solutions of the present invention, the automated volumetric parameter lymph index and MDW can be used as viral biomarkers to help healthcare workers in the out-patient department or fever clinic to rapidly identify those who might be infected with SARS-CoV-2 and to provide valuable information for triage decision making.

Particles such as blood cells can be categorized and counted by a digital image processor. A digital microscope camera can be directed into a flowcell defining a symmetrically narrowing flowpath in which the sample stream flows in a ribbon flattened by flow and viscosity parameters between layers of sheath fluid. A contrast pattern for autofocusing is provided on the flowcell, for example at an edge of a rear illumination opening. The image processor assesses focus accuracy from pixel data contrast. A positioning motor moves the microscope and/or flowcell along the optical axis for autofocusing on the contrast pattern target. The processor then displaces microscope and flowcell by a known distance between the contrast pattern and the sample stream, thus focusing on the sample stream. Blood cell images are collected from that position until autofocus is reinitiated, periodically, by input signal, or when detecting temperature changes or focus inaccuracy in the image data.

A fluid analyzer for analyzing fluid samples comprising one or more analytes and a method of calibrating such. The fluid analyzer includes a control system to control at least one automated valve to pass at least three calibration reagents through a fluid channel to a secondary ion selective electrode, a primary ion selective electrode, and a reference electrode, and determine calibration information using calibration logic from signals generated by a meter, control the at least one automated valve to selectively pass different subsets of the at least three calibration reagents through the fluid channel to the secondary ion selective electrode, the primary ion selective electrode, and the reference electrode, and determine re-calibration information using the signals generated by the meter and at least one of the calibration information and re-calibration logic.

An exemplary mobile impedance-based flow cytometer is developed for the diagnosis of sickle cell disease. The mobile cytometer may be controlled by a computer (e.g., smartphone) application. Calibration of the portable device may be performed using a component of known impedance value. With the developed portable flow cytometer, analysis may be performed on two sickle cell samples and a healthy cell sample. The acquired results may subsequently be analyzed to extract single-cell level impedance information as well as statistics of different cell conditions. Significant differences in cell impedance signals may be observed between sickle cells and normal cells, as well as between sickle cells under hypoxia and normoxia conditions.

Provided herein, among other aspects, are methods and apparatuses for analyzing particles in a sample. In some aspects, the particles can be analytes, cells, nucleic acids, or proteins and can be contacted with a tag, partitioned into aliquots, detected by a ranking device, and isolated. The methods and apparatuses provided herein may include a microfluidic chip. In some aspects, the methods and apparatuses may be used to quantify rare particles in a sample, such as cancer cells and other rare cells for disease diagnosis, prognosis, or treatment.

This disclosure relates to the detection of whole blood hemolysis in a sample of whole blood. More specifically, this disclosure describes detecting hemolysis using one or more novel ratios of intercellular concentrations of whole blood analytes.

Compounds useful as fluorescent or colored dyes are disclosed. The compounds have the following structure (I): or a stereoisomer, tautomer or salt thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, L, L.sup.1, L.sup.2, L.sup.3, L.sup.4, M, M′, m.sup.1, m.sup.2, n, x, y and z are as defined herein. Methods associated with preparation and use of such compounds are also provided. ##STR00001##

A sample cell apparatus for use in spectroscopic determination of an analyte in a body fluid sample includes a first plate member and a second plate member made from an optically clear material. A channel extending into a surface of the first plate member and an opposing surface of the second plate member houses a floating seal, which surrounds a fluid sample chamber. The fluid chamber is closed to define a repeatable optical path-length therethrough by urging the first plate member against the second plate member without compressing the floating seal between the first plate member and the second plate member. The seal channel is vented to prevent fluid pressure from flexing the first plate member or the second plate member. An actuator having an extended foot portion extends over the fluid chamber to help prevent flexing of the first plate member or the second plate member.

Disclosed is a method for detecting an antigen-specific activated T cell comprising: acquiring first information on a particle size and second information on a T cell activation marker for a first measurement sample prepared by mixing in vitro a first specimen separated from a biological sample containing a T cell and an antigen-presenting cell and an antigen reagent containing a predetermined antigen, by measuring the first measurement sample with a flow cytometer; acquiring the first information and the second information for a second measurement sample prepared from a second specimen separated from the biological sample and not containing the antigen reagent, by measuring the second measurement sample with the flow cytometer; detecting a target particle in the first measurement sample based on the first information and the second information on the first measurement sample, and detecting a background particle in the second measurement sample based on the first information and the second information on the second measurement sample; and detecting a cell complex in which the T cell and the antigen-presenting cell adhere to each other in the first measurement sample, the cell complex including a T cell activated by the predetermined antigen, based on a detection result of the target particle and a detection result of the background particle.

The present invention relates to a transduced cancer cell line stably expressing a leukemia tumor antigen, wherein the cancer cell line is cervical cancer cells, breast cancer cells, ovarian cancer cells, pancreatic cancer cells, lung cancer cells, or glioblastoma cells. The transduced adherent cell line of the present invention is useful for many pre-clinical applications such as real time cytotoxicity assay or to test the effects of CAR-T cells that target the tumor antigen. The present invention is exemplified by Hela cell line stably expressing CD19.